Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.70 -0.46 (-1.85%)
Streaming Delayed Price Updated: 10:26 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio ↗
FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits. 
Via Benzinga
News headline image
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals ↗
The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 
Via Stocktwits
News headline image
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗
 
Via Benzinga
News headline image
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.; Sobi
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts ↗
 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals Wilted on Wednesday ↗
Via The Motley Fool
Topics Earnings
News headline image
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Apellis Announces Craig Wheeler to Join the Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
News headline image
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
News headline image
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst ↗
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025. 
Via Benzinga
News headline image
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 28, 2025 ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.